Characteristics of patients (n=63)
| Characteristic | Value |
| Sociodemographic | |
| Male sex, n (%) | 36 (57) |
| Age (years) | 48.0 (17.6) |
| Genetics | |
| Desmosomal mutations, n (%) | 23 (36.5) |
| DSP | 10 (15.9) |
| DSG2 | 5 (7.9) |
| PKP2 | 8 (12.7) |
| Non-desmosomomal mutations, n (%) | 29 (46) |
| FLNC | 14 (22.2) |
| DES | 8 (12.7) |
| TMEM43 | 5 (7.9) |
| LMNA | 2 (3.2) |
| Gene elusive, n (%) | 11 (17.5) |
| Phenotypic form | |
| ARVC, n (%) | 24 (38.1) |
| ALVC, n (%) | 32 (50.8) |
| Biventricular AC, n (%) | 7 (11.1) |
| Clinical features | |
| Left ventricular ejection fraction, n (%) | |
| >52% | 34 (54) |
| ≤52% | 29 (46) |
| VT/VF history | 21 (33.3) |
| ICD, n (%) | 36 (57) |
| Appropriate ICD shocks history | 11 (17.5) |
| Medications at baseline | |
| Beta-blocker, n (%) | 38 (60) |
| ACE inhibitor, n (%) | 21 (33) |
| Sacubitril/valsartan, n (%) | 16 (25) |
| Sotalol, n (%) | 9 (14) |
| Amiodarone, n (%) | 0 (0) |
| Physical activity | |
| Total physical activity (min/day) | 290.2 (123.2) |
| Moderate-to-vigorous intensity (min/day) | 20.9 (16.3) |
| Ventricular tachycardias, n | |
| Sustained VT | 0 |
| RR-NSVT | 35 |
Mean (SD) unless otherwise stated.
AC, arrhythmogenic cardiomyopathy; ALVC, arrhythmogenic left ventricular cardiomyopathy; ARVC, arrhythmogenic right ventricular cardiomyopathy; DES, desmin; DSG2, desmoglein-2; DSP, desmoplakin; FLNC, filamin C; ICD, implantable cardioverter defibrillator; LMNA, lamin A/C; LVEF, left ventricular ejection fraction; PKP2, plakophilin-2; RR-NSVT, rapid-rate non-sustained ventricular tachycardia; TMEM43, transmembrane protein 43; VT/VF, ventricular tachycardia/ventricular fibrillation.